NTRC Therapeutics, a biotech company specialized in the research and development of kinase inhibitors and degraders, will continue under the name Crossfire Oncology.
Founded in 2011 as Netherlands Translational Research Center, NTRC originally pursued a dual business model providing services to
Joost C.M. Uitdehaag, Jeffrey J. Kooijman, Jeroen A.D.M. de Roos, Martine B.W. Prinsen, Jelle Dylus, Nicole Willemsen-Seegers,Yusuke Kawase, Masaaki Sawa, Jos de Man, Suzanne J.C. van Gerwen, Rogier C. Buijsman, and Guido J.R. Zaman. Molecular Cancer Therapeutics. 2019
Marion A.A. Libouban, Jeroen A.D.M. de Roos, Joost C.M. Uitdehaag, Nicole Willemsen-Seegers, Sara Mainardi, Jelle Dylus, Jos de Man, Bastiaan Tops, Jules P.P. Meijerink, Zuzana Storchová, Rogier C. Buijsman, René H. Medema, Guido J.R. Zaman. Oncotarget. 2017
Joost C.M. Uitdehaag, Jos de Man, Nicole Willemsen-Seegers, Martine B.W. Prinsen, Marion A.A. Libouban, Jan Gerard Sterrenburg, Joeri J.P. de Wit, Judith R.F. de Vetter, Jeroen A.D.M. de Roos, Rogier C. Buijsman and Guido J.R. Zaman. Journal of Molecular Biology. 2017
Guido J.R. Zaman, Jeroen A.D.M. de Roos, Marion A.A. Libouban, Martine B.W. Prinsen, Jos de Man, Rogier C. Buijsman, and Joost C.M. Uitdehaag. Molecular Cancer Therapeutics. 2017
A. R. R. Maia, J. de Man, U. Boon, A. Janssen, J.-Y. Song, M. Omerzu, J. G. Sterrenburg, M. B. W. Prinsen, N. Willemsen-Seegers, J. A. D. M. de Roos, A. M. van Doornmalen, J. C. M. Uitdehaag, G. J. P. L. Kops, J. Jonkers, R. C. Buijsman, G. J. R. Zaman and R. H. Medema. Annals of Oncology. 2015
Joost CM Uitdehaag, Folkert Verkaar, Husam Alwan, Jos de Man, Rogier C Buijsman and Guido JR Zaman. British Journal of Pharmacology. 2011
Yvonne Grobben, Jos de Man, Antoon M. van Doornmalen, Michelle Muller, Nicole Willemsen-Seegers, Diep Vu-Pham, Winfried R. Mulder, Martine B. W. Prinsen, Joeri de Wit, Jan Gerard Sterrenburg, Freek van Cauter, Judith E. den Ouden, Anne M. van Altena, Leon F. Massuger, Joost C. M. Uitdehaag, Rogier C. Buijsman and Guido J. R. Zaman. Frontiers in Immunology. 2021
Feugiat venenatis placerat consequat metus eu ornare vitae viverra dui volutpat purus augue blandit amet nunc ut lacinia.
Eget ullamcorper neque sem pellentesque condimentum tellus vulputate sed netus erat lacus proin mauris scelerisque quisque aliquam.